The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep responses with initial ibrutinib-venetoclax, while sparing early responders from additional toxicity.